Abstract
It has been proved that the pathogenesis and deterioration of renal diseases particularly including nephritis are related to the abnormalities blood coagulation or the fibrinolytic system, and various types of anti-coagulant therapy are applied to the treatment for these diseases. Trimetazidine is known to have anti-platelet activity. We studied its effect on various kinds of nephritis by administering a large dose of 45 mg/day.
Decrease in proteinuria was observed in 2 out of 7 patients with chronic glomerulonephritis, 2 out of 3 patients with nephrotic syndrome and 1 patient with nephritis and purpura. More significant effect on decrease in red blood cells in urine was noted in 3 out of 7 cases with chronic glomerulonephritis, 1 out of 3 cases with nephrotic syndrome and 1 lupus nehritis and nephritis and purpura. Thus, the drug was considered to be effective for the treatment of proliferative nephritis.
